Partricin compsn. for treatment of benign prostatic hypertrophy - pref. compsn. contains the methyl ester opt. as water-soluble complexes with surface active cpds. e.g. sodium lauryl sulphate

摘要

Compsn. for treatment of benign hypertrophy of the prostate in human males contains a cpd. chosen from partricin, 1-6C alkyl esters of partricin and 1-6C alkyl esters of partricin and 1-6C alkyl esters of partricin N-mono- or N, N-di-substd. by 1-6C alkyl or carboxylic acyl gps. in association with a solid or liq. pharmaceutical vehicle or diluent. The active cpd. may be in the form of a water-soluble complex with a cpd. chosen from benzalkonium chloride, sodium lauryl sulphate, sodium tetradecyl sulphate, sodium desoxycholate and sodium dehydrocholate. Used for treatment of benign prostatic hypertrophy. The compsn. reduces the gland to normal size and appearance. The treatment of the present invention avoids the side-effects and uncertainty of androgen or estrogen hormone treatment and avoids surgery. In benign hypertrophy of the prostate histo-clinical studies have shown a significant increase in cholesterol levels, and partricin and its derivs. have hypocholesterolenic activity. The compsn. may be administered orally, parenterally or rectally using classical formulations. Clinical tests are described, which show the good results obtd. by use of the compsn.